LORYNA
Clinical safety rating
cautionComprehensive clinical and safety monograph for LORYNA (LORYNA).
Selective mineralocorticoid receptor antagonist, blocking aldosterone binding to the mineralocorticoid receptor in epithelial and nonepithelial tissues.
| Metabolism | Hepatic via CYP3A4 |
| Excretion | Primarily excreted via feces (80%) after biliary elimination; renal excretion accounts for approximately 10% as unchanged drug and metabolites. |
| Half-life | Terminal elimination half-life is 18–24 hours in healthy adults; may be prolonged in severe hepatic impairment. |
| Protein binding | High protein binding (>99%) mainly to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.4–0.6 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability is approximately 50–60% due to extensive first-pass metabolism. |
| Onset of Action | Oral: 30–60 minutes for clinical effect. |
| Duration of Action | Duration of action is 8–12 hours after single dose; sustained effects with repeated dosing due to long half-life. |
| Molecular Weight | 414.5 |
5 mg orally once daily, with or without food. Maximum dose 10 mg once daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR 15-29 mL/min: 2.5 mg once daily. GFR <15 mL/min or dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: Not recommended. |
| Pediatric use | Not established for patients under 18 years. |
| Geriatric use | Start at 2.5 mg once daily due to increased sensitivity; titrate based on response and tolerability. |
| 1st trimester | Avoid use during first trimester due to risk of fetal harm; animal studies show embryotoxicity. |
| 2nd trimester | Avoid use; potential risk of fetal toxicity and preterm closure of ductus arteriosus. |
| 3rd trimester | Avoid use in third trimester due to risk of premature closure of ductus arteriosus and renal dysfunction in fetus. |
Clinical note
Comprehensive clinical and safety monograph for LORYNA (LORYNA).
| Placental transfer | Crosses placenta; documented in animal and human studies. |
| Breastfeeding | Excreted in breast milk in low levels; consider risk of adverse effects in infant (e.g., gastrointestinal irritation). Use caution and monitor infant. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects (anencephaly, spina bifida) and cardiovascular anomalies based on human data from antiepileptic drugs similar to topiramate. Second/third trimester: Risk of fetal growth restriction, low birth weight, and possibly preterm delivery. Overall, topiramate is considered teratogenic (Pregnancy Category D). |
| Fetal Monitoring | Maternal: Baseline and periodic serum topiramate levels, renal function, electrolytes, and liver function. Monitor for metabolic acidosis, glaucoma, and cognitive side effects. Fetal: Detailed ultrasound for structural anomalies in first trimester, growth scans in second/third trimesters. Consider amniocentesis if indicated. |
| Fertility Effects | In women, topiramate may cause reversible menstrual irregularities and anovulation, potentially reducing fertility. In men, no significant impact on spermatogenesis reported. Caution in women planning pregnancy due to teratogenicity. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to drug or excipientsSevere hepatic impairmentActive peptic ulcer diseaseCoagulation disordersKnown intrathecal or epidural route for high-dose
| Precautions | Hyperkalemia, Renal impairment, Additive effect with other potassium-sparing diuretics or ACE inhibitors/ARBs |
| Food/Dietary | Avoid grapefruit and grapefruit juice. No other significant food interactions. Maintain consistent dietary potassium intake. |
| Clinical Pearls | LORYNA (drospirenone/ethinyl estradiol) is an oral contraceptive. Monitor potassium levels in patients with renal or hepatic impairment or on NSAIDs. Do not use in patients with hyperkalemia. Use with caution in patients predisposed to hyperkalemia. |
| Patient Advice | Take one tablet daily at the same time. Do not skip doses. · Use backup contraception if you miss a pill or have vomiting/diarrhea. · Avoid smoking, especially if over 35, due to increased cardiovascular risk. · Notify your doctor if you experience leg pain, shortness of breath, or severe headache. · This medication does not protect against HIV or other STDs. |
Loading safety data…